EA201000053A1 - Новые антитела - Google Patents

Новые антитела

Info

Publication number
EA201000053A1
EA201000053A1 EA201000053A EA201000053A EA201000053A1 EA 201000053 A1 EA201000053 A1 EA 201000053A1 EA 201000053 A EA201000053 A EA 201000053A EA 201000053 A EA201000053 A EA 201000053A EA 201000053 A1 EA201000053 A1 EA 201000053A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
binding fragments
new antibodies
present
antigen
Prior art date
Application number
EA201000053A
Other languages
English (en)
Inventor
Джонатан Генри Эллис
Пол Эндрю Хэмблин
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA201000053A1 publication Critical patent/EA201000053A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к антителам или их антигенсвязывающим фрагментам, специфично связывающим рецептор человеческого инсулиноподобного фактора роста (IGF-1R). Также раскрыты препараты антител, содержащие антитела или антигенсвязывающие фрагменты по изобретению. Способы получения таких антител или антиген-связывающих фрагментов и их применения также включены в объем настоящего изобретения.
EA201000053A 2007-08-01 2008-07-28 Новые антитела EA201000053A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95321007P 2007-08-01 2007-08-01
PCT/EP2008/059900 WO2009016164A1 (en) 2007-08-01 2008-07-28 Novel antibodies

Publications (1)

Publication Number Publication Date
EA201000053A1 true EA201000053A1 (ru) 2010-08-30

Family

ID=40029299

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000053A EA201000053A1 (ru) 2007-08-01 2008-07-28 Новые антитела

Country Status (11)

Country Link
US (1) US20110262430A1 (ru)
EP (1) EP2190879A1 (ru)
JP (1) JP2010534710A (ru)
KR (1) KR20100057021A (ru)
CN (1) CN101855244A (ru)
AU (1) AU2008281801A1 (ru)
BR (1) BRPI0814471A2 (ru)
CA (1) CA2694055A1 (ru)
EA (1) EA201000053A1 (ru)
MX (1) MX2010001237A (ru)
WO (1) WO2009016164A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CN103396488A (zh) 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 抗igf抗体
ES2672121T3 (es) 2009-10-07 2018-06-12 Macrogenics, Inc. Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
KR20150031217A (ko) * 2011-12-15 2015-03-23 더 로얄 인스티튜션 포 디 어드밴스먼트 오브 러닝/맥길 유니버시티 가용성 igf 수용체 fc 융합 단백질 및 이의 용도
WO2013106603A1 (en) * 2012-01-10 2013-07-18 Expression Pathology, Inc. Srm/mrm assay for the insulin receptor protein
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP3057986B1 (en) * 2013-10-17 2017-12-27 National University of Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
CA2965414C (en) * 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
AU2022331476A1 (en) * 2021-08-18 2024-02-22 The Regents Of The University Of California Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
AU2005269759A1 (en) * 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
BRPI0611445A2 (pt) * 2005-05-09 2010-09-08 Glycart Biotechnology Ag molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
WO2008098115A2 (en) * 2007-02-07 2008-08-14 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same

Also Published As

Publication number Publication date
CA2694055A1 (en) 2009-02-05
CN101855244A (zh) 2010-10-06
WO2009016164A1 (en) 2009-02-05
JP2010534710A (ja) 2010-11-11
EP2190879A1 (en) 2010-06-02
MX2010001237A (es) 2010-03-01
KR20100057021A (ko) 2010-05-28
US20110262430A1 (en) 2011-10-27
AU2008281801A1 (en) 2009-02-05
BRPI0814471A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
EA201000053A1 (ru) Новые антитела
HRP20190312T1 (hr) Vežući proteini, uključujući protutijela, derivate protutijela i fragmente protutijela, koji se specifično vežu na cd154 i njihova upotreba
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201000471A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
MX360543B (es) Anticuerpos st-2 humanos solubles y ensayos.
PH12013502205A1 (en) Antibodies to il-6 and their uses
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA201270491A1 (ru) Антитела, специфически связывающие рецептор ерна2
EA201500204A1 (ru) Антитела к ox40 и способы их применения
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
UA106070C2 (ru) Антитело, которое специфически связывается с egfr и her3
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2013188693A8 (en) Antigen binding constructs to cd3
IN2014CN03936A (ru)
WO2010113117A3 (en) Preparation of isolated agonist anti-edar monoclonal antibodies
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
WO2008098917A3 (en) Novel antibodies against igf-ir
MA34004B1 (fr) Protéines de liaison à cd127
EA201390537A1 (ru) Антигенсвязывающие белки, связывающиеся с онкостатином м (osm)
EA200900991A1 (ru) Новые антитела против igf-1r
WO2013059206A3 (en) Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii)
EA202091088A1 (ru) Антитела и химерные антигенные рецепторы, специфические для b-клеточного антигена созревания
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2